Geron Climbs After FDA Lifts Partial Hold on Cancer Trial

Geron Corp. (GERN), a biotechnology company with no marketed products, rose the most in about three months after U.S. regulators removed a partial hold on a clinical trial for its drug to treat a rare form of leukemia.

Geron increased 21 percent to $3.15 at the close in New York. The Menlo Park, California-based company has almost tripled in the past 12 months.

Geron is developing its drug imetelstat for a form of leukemia called myelofibrosis. The Food and Drug Administration lifted the freeze after the Mayo Clinic, the trial’s sponsor, gave the agency more information about the reversibility of the experimental drug’s toxic effect on the liver, Geron said in a statement today.

Myelofibrosis is a bone marrow cancer that can lead to severe anemia, fatigue and an enlarged spleen and liver. After patients taking the drug showed low-grade liver function test abnormalities, the FDA halted dosing of imetelstat for all patients except those who were showing a benefit from it.

Geron’s clinical trials in two other diseases, thrombocythemia and multiple myeloma, remain on hold and it can’t start any new trials in the U.S.

“The company is working diligently to seek release of the full clinical hold,” Geron said in the statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Drew Armstrong, Andrew Pollack

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.